MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Juvenile Huntington’s Disease in Tunisia: Clinical Diversity and Literature review

H. Nehdi, E. Chebbi, F. Nabli, Z. Saied, S. Ben Sassi, R. Amouri (Tunis, Tunisia)

Meeting: 2022 International Congress

Abstract Number: 629

Keywords: Chorea (also see specific diagnoses, Huntingtons disease, etc): Clinical features, Chorea (also see specific diagnoses, Huntingtons disease, etc): Genetics, Magnetic resonance imaging(MRI)

Category: Huntington's Disease

Objective: We conducted the first JHD clinical and molecular features in Tunisia and North Africa, contributing to better understanding the diverse manifestation of the disease than previously shown

Background: Huntington’s disease (HD) is a rare, autosomal dominant neurodegenerative disease characterized by motor, cognitive, and psychiatric symptoms. Although HD usually appears in adulthood, a juvenile form (JHD) that usually begins before the age of 21 is present in 5-10% of cases. Recently a more refined terminology to refer specifically to children and young adolescents diagnosed with HD has been adopted. The term “pediatric HD” has been introduced to refer to young people affected by HD who are currently under the age of 18. The genetic diagnosis of HD is confirmed in all patients with a pathological CAG triplet expansion in HTT that exceeds 36 repetitions

Method: From a cohort of 180 HD patients admitted to the National institute Mongi Ben Hmida of Neurology, 4 patients were selected according to three inclusion criteria of Juvenile or Pediatric Huntington’s Disease (JHD or PHD)
After informed consent, genomic DNA was extracted from peripheral blood leukocytes according to standard protocol, and genetic testing for HD was carried out by Triplet-primed PCR  and analyzed with Genemapper Software v3.7.

Results: From 180 HD patients, we include 4 young patients coming from 4 unrelated families and from different regions of Tunisia. Three are Pediatric (Proportion 1.66 %) and 1 Juvenile (Proportion 0.55%)
There are three young girls and one boy (sex ratio 3:1 in favor of female patients). The mean age of onset of HD symptoms was 11±3 years. The disease had affected them in different ways.
For the four cases, three developed seizures associated with psychomotor regression in childhood (PHD), one case had mild chorea of the trunk and arms at onset (18 years) and she developed seizures in early adulthood (JHD). The three PHD cases with seizures have a paternal history of HD whereas the patient who developed seizures at the age of 21 has a maternal history of HD.

Conclusion: Given the complexity of the clinical picture of JHD, we emphasize the challenges of making a disease diagnosis. Furthermore, the number of  CAG repeats suggests that factors other than genetic may contribute to the early manifestation of JHD.
​​​​​​

References: Ashley A. Moeller, M. V. (2021). Patients With Extreme Early Onset Juvenile Huntington Disease Can Have Delays in Diagnosis: A Case Report and Literature review. Child Neurology Open , 2329048X2110361.
Emilia Mabel Gatto, V. P. (2016, January). Juvenile Huntington’s Disease in Argentina. Arquivos di Neuro-psiquiatria .
Gambardella A, M. M. (2001). Juvenile Hunting ton’s disease presenting as progressive myoclonic epilepsy. Neurology , 57: 708-11.
Gonzalez-Alegre P, A. A. (2006). Clinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the litterature. Journal of Cild Neurology , 21 (3) 223-9.
hjhkjlk. (2010). hkjkjlkj. tunis: hgjhkl.
Ho VB, C. H. (1995). Juvenile Huntington disease: CT and MR features. AJNR Am J Neuroradiol , 16(7):1405–12 .
Jannis Achenbach, C. T. (2020). Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series. Brain Sci. , 10, 340.
Keum JW, S. A. (2016). The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease. Am J Hum Genet , 98 (2);287-298.
Koustsis G, K. G. (2013). The challenge of Juvenile Huntington disease: to test or not to test. Neurology , 80 (11): 990-6.
Lanciego, J. L. (2012). Functional Neuroanatomy of the Basal Ganglia. Cold Spring Harbor Perspectives in Medicine 2 , a009621–a009621.
Mark E. Landau, K. R. (2003). EEG characteristics in juvenile Huntington’s disease: a case report and review of litterature. Epileptic Disord , 5: 145-8.
O.Quarrell, K. O. (2012). The prevalence of Juvenile Huntington’s disease: a review of the litterature and meta-analysis. PLoS currents 4 , 742-743.
O.W.J.Quarrell, M. N. (2019 ). Defining pediatric Huntington Disease: time to abondon the term Juvenile Huntington Disease? Movement Disorder , 584-585.
Oliver W. J. Quarrell, M. A.-M. (2019). Defining Pediatric Huntington Disease: Time to Abandon the Term Juvenile Huntington Disease. Movement Disorders .
Patrick Arraj, B. K. (2021). MRI findings in juvenile Huntington’s disease. Radiology Case Reports 16 , 113-115.
Patrick Arraj, K. R. (2021). MRI findings in juvenile Huntington’s disease. Radiology Case Reports , 16: 113-115.
Quarrell OW, N. M. (2013). Managing juvenile Huntington’s disease. Neurodegener Dis Manag. , 3(3):102217/ nmt13.18.
Quarrell OW, N. M. (2013). Managing juvenile Huntington’s disease. Neurodegene Dis Manag , 3(3); 1-16.
Quarrell, O., Nance, M., Nopoulos, P., Reilmann, R., Oosterloo, M., Tabrizi, S., et al. (2019). Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease? Movment Disorder. Off. Journal of Movment Disorder Social .
Roos, R. (2010). Huntington’s Disease: A clinical review. Orphanet J. Rare Dis , 5-40.
Schultz JL, M. A. (2020). The association between CAG repeat length and age of onset of juvenile-onset Huntington’s Disease. Brain Sci , ; 10 (9) 575.
Seizures in Juvenile Hungtington’s Disease: Frequency and characterization in a multicenter CohortMouvement Disorders Vol. 27.
Sgita Leinskiene, D. R. (2020). Juvenile Huntington’s disease: two case reports and a review of the literature. Journal of Medical Case Reports , 14:173.
Sigita Lesinskienė, D. R. (2020). Juvenile Huntington’s disease: two case reports and a review of the literature. Journal of Medical Case Reports , 14:173.
Sigita Lesinskienė, D. R. (2020). Juvenile Huntington’s disease: two case reports and a review of the literature. Journal of Medical Case Reports , 14:173.
Solberg OK, F. P. (2018). Age at death and causes of death in patients with Huntington Disease in Norway in 1986-2015. Journal of Huntongton Disease , 7 (1): 77-86.
Thomas Cronina, A. R. (2019). Clinical Presentation and Features of Juvenile-Onset Huntington’s Disease: A Systematic Review. Journal of Huntington’s Disease , 171–179.
Thomas Cronina, A. R. (2019). Clinical Presentation and Features of Juvenile-onset Huntington’s Disease: A Systematic Review. Journal of Huntington’s Disease , 171–179.
Van Dijk, J., van der Velde, E., Roos, R., & Bruyn, G. (1986). Juvenile Huntington disease. Human genetics , (73): 235–239.
Walker, F. (2007). Huntington’s Disease. Lancet , 218-228.

To cite this abstract in AMA style:

H. Nehdi, E. Chebbi, F. Nabli, Z. Saied, S. Ben Sassi, R. Amouri. Juvenile Huntington’s Disease in Tunisia: Clinical Diversity and Literature review [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/juvenile-huntingtons-disease-in-tunisia-clinical-diversity-and-literature-review/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/juvenile-huntingtons-disease-in-tunisia-clinical-diversity-and-literature-review/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley